Abstract
Reverse phase protein arrays (RPPAs) emerged as a very useful tool for high-throughput screening of protein expression in large numbers of small specimen. Similar to other protein chemistry methods, antibody specificity is also a major concern for RPPA. Currently, testing antibodies on Western blot for specificity and applying serial dilution curves to determine signal/concentration linearity of RPPA signals are most commonly employed to validate antibodies for RPPA applications. However, even the detection antibodies fulfilling both requirements do not always give the expected result. Chemically synthesized small interfering RNAs (siRNAs) are one of the most promising and time-efficient tools for loss-of-function studies by specifically targeting the gene of interest resulting in a reduction at the protein expression level, and are therefore used to dissect biological processes. Here, we report the utilization of siRNA-treated sample lysates for the quantification of a protein of interest as a useful and reliable tool to validate antibody specificity for RPPAs. As our results indicate, we recommend the use of antibodies which give the highest dynamic range between the control siRNA-treated samples and the target protein (here: EGFR) siRNA-treated ones on RPPAs, to be able to quantify even small differences of protein abundance with high confidence.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Paweletz, C.P., et al., Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene, 2001. 20(16): 1981–9.
Charboneau, L., et al., Utility of reverse phase protein arrays: applications to signalling pathways and human body arrays. Brief Funct Genomic Proteomic, 2002. 1(3): 305–15.
Spurrier, B., S. Ramalingam, and S. Nishizuka, Reverse-phase protein lysate microarrays for cell signaling analysis. Nat Protoc, 2008. 3(11): 1796–808.
Mittal, V., Improving the efficiency of RNA interference in mammals. Nat Rev Genet, 2004. 5(5): 355–65.
Fire, A., et al., Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 1998. 391(6669): 806–11.
Elbashir, S.M., et al., Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 2001. 411(6836): 494–8.
Sahin, O., et al., Combinatorial RNAi for quantitative protein network analysis. Proc Natl Acad Sci USA, 2007. 104(16): 6579–84.
Sahin, O., et al., Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance. BMC Syst Biol, 2009. 3: 1.
Frohlich, H., et al., Deterministic Effects Propagation Networks for reconstructing protein signaling networks from multiple interventions. BMC Bioinformatics, 2009. 10: 322.
Spurrier, B., et al., Antibody screening database for protein kinetic modeling. Proteomics, 2007. 7(18): 3259–63.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Mannsperger, H., Uhlmann, S., Korf, U., Sahin, Ö. (2011). Utilization of RNAi to Validate Antibodies for Reverse Phase Protein Arrays. In: Korf, U. (eds) Protein Microarrays. Methods in Molecular Biology, vol 785. Humana Press. https://doi.org/10.1007/978-1-61779-286-1_4
Download citation
DOI: https://doi.org/10.1007/978-1-61779-286-1_4
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-285-4
Online ISBN: 978-1-61779-286-1
eBook Packages: Springer Protocols